Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 255

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 255
---
 retroactively
within these financial statements to reflect the Split. On March 20, 2025, at the general meeting of the Company's shareholders, the shareholders
of the Company approved an increase of the authorized share capital of the Company and cancellation of the par value of the Ordinary Shares
and the Company’s preferred shares (see Note 15).

| d. | Going concern and management plans |

The accompanying financial statements
have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical
trials, and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent
of the Company’s future operating losses and the timing of becoming profitable are uncertain. The Company has incurred profit of
$5,231 for the year ended December 31, 2024. As of December 31, 2024, the Company’s accumulated deficit was $41,716. The Company
has funded its operations to date primarily through equity financing, loans and the issuance of convertible notes. Management expects
that the Company will continue to generate losses from the development, clinical trials, regulatory activities of its product and from
the general administration of its business, which will result in negative cash flow from operating activity.

<div align='center'>F-7</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 1:- | GENERAL (Cont.) |

While the Company has been successful
in raising financing in the past, it is not probable that the Company will be able to successfully obtain additional financing on a timely
basis on terms acceptable to the Company, or will provide the Company with sufficient funds to meet its objective.

Such conditions raise substantial
doubts about the Company’s ability to continue as a going concern. Management’s plans include, but are not limited to, initial
public offering (the “IPO”) in the US.

In addition, in the event the Company
is unable to have its convertible notes converted as planned or their repayment date deferred, the Company will not have sufficient cash
flows and liquidity to finance its business operations as currently contemplated. If such sufficient financing or payment deferral is
not received timely, the Company would then need to pursue a plan to license or